These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Development of resistance to biologic therapies with reference to IFN-β.
    Author: Farrell RA, Marta M, Gaeguta AJ, Souslova V, Giovannoni G, Creeke PI.
    Journal: Rheumatology (Oxford); 2012 Apr; 51(4):590-9. PubMed ID: 22258390.
    Abstract:
    All biotherapeutics have the potential to generate anti-drug antibodies (ADAs) in patients. The main factors leading to an immune response are thought to be product, treatment and patient related. In this review, reasons for the formation of ADAs, and particularly neutralizing antibodies (NAbs), are considered, with a focus on IFN-β as a well-studied example. The time course for the production of NAbs, the measurement of NAbs, the defining of IFN-β responders and non-responders, the implications for disease progression in patients, and future methods for avoiding the production of ADAs and of tolerizing patients are considered.
    [Abstract] [Full Text] [Related] [New Search]